$8.03
0.00% yesterday
Nasdaq, Nov 27, 12:30 am CET
ISIN
US75943R1023
Symbol
RLAY

Relay Therapeutics Inc Stock price

$8.03
+0.65 8.81% 1M
+5.12 175.95% 6M
+3.91 94.90% YTD
+3.27 68.70% 1Y
-10.38 56.38% 3Y
-46.00 85.14% 5Y
-27.02 77.09% 10Y
-27.02 77.09% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.02 0.25%
ISIN
US75943R1023
Symbol
RLAY
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$795.4m
Net debt
positive
Cash
$596.4m
Shares outstanding
172.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
166.5 | 109.3
EV/Sales
95.1 | 62.4
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
89.3%
Return on Equity
-43.4%
ROCE
-51.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$8.4m | $12.7m
EBITDA
$-322.8m | $-319.1m
EBIT
$-327.1m | $-320.4m
Net Income
$-297.6m | $-298.9m
Free Cash Flow
$-248.9m
Growth (TTM | estimate)
Revenue
-76.5% | 27.3%
EBITDA
50.7% | 13.1%
EBIT
50.5% | 14.0%
Net Income
50.7% | 11.5%
Free Cash Flow
11.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,863.0% | -2,505.1%
EBIT
-3,914.4%
Net
-3,561.4% | -2,346.2%
Free Cash Flow
-2,978.3%
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
14.9%
Employees
197
Rev per Employee
$50.0k
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
8.36 8.36
76% 76%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
54% 54%
734%
- Research and Development Expense 283 283
51% 51%
3,391%
-323 -323
51% 51%
-3,861%
- Depreciation and Amortization 4.29 4.29
22% 22%
51%
EBIT (Operating Income) EBIT -327 -327
50% 50%
-3,913%
Net Profit -298 -298
51% 51%
-3,560%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
Seeking Alpha
6 days ago
Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.
Neutral
GlobeNewsWire
21 days ago
Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated  breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company's Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Re...
Neutral
GlobeNewsWire
24 days ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November: Guggenheim's 2nd Annual Healthcare Innovation Confe...
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 197
Founded 2015
Website relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today